TWI900533B - 針對含有g12v突變之ras之hla第ii類限制性t細胞受體 - Google Patents

針對含有g12v突變之ras之hla第ii類限制性t細胞受體

Info

Publication number
TWI900533B
TWI900533B TW110106886A TW110106886A TWI900533B TW I900533 B TWI900533 B TW I900533B TW 110106886 A TW110106886 A TW 110106886A TW 110106886 A TW110106886 A TW 110106886A TW I900533 B TWI900533 B TW I900533B
Authority
TW
Taiwan
Prior art keywords
seq
amino acid
acid sequence
chain
leu
Prior art date
Application number
TW110106886A
Other languages
English (en)
Chinese (zh)
Other versions
TW202140537A (zh
Inventor
諾姆 萊文
拉彌 約瑟夫
畢曼 C 巴黎雅
史帝文 A 羅森伯格
Original Assignee
美國衛生與公眾服務部
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美國衛生與公眾服務部 filed Critical 美國衛生與公眾服務部
Publication of TW202140537A publication Critical patent/TW202140537A/zh
Application granted granted Critical
Publication of TWI900533B publication Critical patent/TWI900533B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
TW110106886A 2020-02-26 2021-02-26 針對含有g12v突變之ras之hla第ii類限制性t細胞受體 TWI900533B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062981856P 2020-02-26 2020-02-26
US62/981,856 2020-02-26

Publications (2)

Publication Number Publication Date
TW202140537A TW202140537A (zh) 2021-11-01
TWI900533B true TWI900533B (zh) 2025-10-11

Family

ID=74885105

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110106886A TWI900533B (zh) 2020-02-26 2021-02-26 針對含有g12v突變之ras之hla第ii類限制性t細胞受體

Country Status (12)

Country Link
US (1) US20230159614A1 (cg-RX-API-DMAC7.html)
EP (1) EP4110804A1 (cg-RX-API-DMAC7.html)
JP (1) JP7742354B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220143939A (cg-RX-API-DMAC7.html)
CN (1) CN115244075A (cg-RX-API-DMAC7.html)
AU (1) AU2021225872A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022016661A2 (cg-RX-API-DMAC7.html)
CA (1) CA3169086A1 (cg-RX-API-DMAC7.html)
GB (1) GB2610069B (cg-RX-API-DMAC7.html)
MX (1) MX2022010157A (cg-RX-API-DMAC7.html)
TW (1) TWI900533B (cg-RX-API-DMAC7.html)
WO (1) WO2021173902A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023550515A (ja) * 2020-11-24 2023-12-01 シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド Ras突然変異体エピトープペプチドおよびras突然変異体を認識するt細胞受容体
JP2024507929A (ja) 2021-02-25 2024-02-21 アラウノス セラピューティクス インコーポレイテッド 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201920251A (zh) * 2017-09-20 2019-06-01 美國衛生與公眾服務部 針對突變ras之hla第ii類限制性t細胞受體

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
SG10201913868XA (en) * 2015-09-15 2020-03-30 The United States Of America As Represented By The Secretary T cell receptors recognizing hla-cw8 restricted mutated kras
SG11201900654QA (en) * 2016-08-02 2019-02-27 Us Health Anti-kras-g12d t cell receptors
MX2020005765A (es) * 2017-12-04 2020-09-25 Us Health Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado.
US20210061876A1 (en) * 2017-12-29 2021-03-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft T cell receptors for tumor specific proteasome splice variants and uses thereof
GB201804724D0 (en) * 2018-03-23 2018-05-09 Univ Oslo Hf Method of diagnosing cceliac disease
WO2019231326A1 (en) * 2018-05-31 2019-12-05 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n.LUMC) Teipp neoantigens and uses thereof
JP2024507929A (ja) * 2021-02-25 2024-02-21 アラウノス セラピューティクス インコーポレイテッド 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201920251A (zh) * 2017-09-20 2019-06-01 美國衛生與公眾服務部 針對突變ras之hla第ii類限制性t細胞受體

Also Published As

Publication number Publication date
MX2022010157A (es) 2022-10-18
US20230159614A1 (en) 2023-05-25
JP7742354B2 (ja) 2025-09-19
BR112022016661A2 (pt) 2022-10-11
GB2610069B (en) 2025-04-16
GB2610069A (en) 2023-02-22
KR20220143939A (ko) 2022-10-25
JP2023527613A (ja) 2023-06-30
TW202140537A (zh) 2021-11-01
WO2021173902A1 (en) 2021-09-02
CN115244075A (zh) 2022-10-25
EP4110804A1 (en) 2023-01-04
GB202212195D0 (en) 2022-10-05
AU2021225872A1 (en) 2022-09-15
CA3169086A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
JP7620676B2 (ja) 突然変異rasに対するhlaクラスi拘束性t細胞受容体
TWI900528B (zh) 針對含有g12d突變之ras之hla第i類限制性t細胞受體
TWI902755B (zh) 針對含有g12v突變之ras之hla第i類限制性t細胞受體
JP7742354B2 (ja) G12v変異を有するrasに対するhlaクラスii拘束性t細胞受容体
TW202029971A (zh) 針對突變ras之hla-a3–限制性t細胞受體
CN117957245A (zh) 识别p53中的c135y、r175h或m237i突变的t细胞受体
KR102934104B1 (ko) G12r 돌연변이를 갖는 ras에 대한 hla 클래스 ii-제한된 t 세포 수용체
CN116322734A (zh) 针对具有g12d突变的ras的hla ii类限制性drb t细胞受体
TW202229327A (zh) 針對含有g13d突變之ras之hla第ii類限制性dq t細胞受體
TWI900647B (zh) 識別p53中r273c或y220c突變的t細胞受體
EP4182029B1 (en) HLA-restricted class II DRB T lymphocyte receptors directed against RAS, including a G12V mutation
RU2849866C1 (ru) T-клеточные рецепторы, рестриктированные по hla класса i, против ras с мутацией g12d